United States Deep Brain Stimulation in Parkinson’s Disease Market Insights Forecasts to 2033

• The U.S. Deep Brain Stimulation in Parkinson’s Disease Market Size was valued at USD 521.5 Million in 2023.
• The Market is growing at a CAGR of 7.15% from 2023 to 2033
• The U.S. Deep Brain Stimulation in Parkinson’s Disease Market Size is expected to reach USD 1040.5 Million by 2033

The United States Deep Brain Stimulation in Parkinson’s Disease Market is anticipated to exceed USD 1040.5 Million by 2033, growing at a CAGR of 7.15% from 2023 to 2033. The growing prevalence of Parkinson’s disease (PD), technological advancements, and government funding for R&D activities are driving the growth of the deep brain stimulation in Parkinson’s disease market in the US.      

Market Overview

Deep brain stimulation is the surgical implantation of a device that sends electrical signals to the parts of the brain in charge of controlling bodily movements. DBS devices assist in lessening the stiffness and tremors brought on by Parkinson’s disease, thereby helping to reduce any potential negative effects caused by taking drugs. DBS devices are quite successful in reducing the tremors connected to Parkinson's disease. In patients with Parkinson's disease (PD), they stimulate the basal ganglia electrically, which suppresses neuronal activity and is usually spontaneous. According to the Parkinson’s Foundation Statistics report, in the United States, around one million individuals suffer from Parkinson's disease (PD). By 2030, this figure is anticipated to increase to 1.2 million. Parkinson's is the second most prevalent neurological illness in United States. Thus, the increasing prevalence of Parkinson’s disease across the region supports the market demand for deep brain stimulation. New opportunities are being created by innovations including rechargeable Implantable Pulse Generators (IPGs), multitarget stimulation, robot-assisted implantation, improved microelectrode designs, personalized directed programming, and integration of Magnetic Resonance Imaging (MRI) that not only improve the accuracy and efficacy of DBS surgeries but also open the door to more individualized and successful therapies.

Report Coverage

This research report categorizes the market for the US deep brain stimulation in Parkinson’s disease market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States deep brain stimulation in Parkinson’s disease market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US deep brain stimulation in Parkinson’s disease market.

Driving Factors

The growing prevalence of Parkinson’s disease (PD) due to various factors including cases of head injury, genetic factors, and age-related risk is driving the market demand. The technological advancements in DBS and the development of innovative technology including enhanced microelectrode designs, multitarget stimulation, rechargeable Implantable Pulse Generators (IPGs), robot-assisted implantation, personalized directed programming, and introduction of magnetic resonance imaging (MRI) are significantly driving the market growth.Further, the support from government for funding as well as their contribution for enhancing the accessibility of DBS technology for the treatment of patients are propelling the market.           

Restraining Factors

The high expense of surgery and the length of time it takes for product approvals from different regulatory bodies are restraining the market for deep brain stimulation in Parkinson’s disease.

Market Segmentation

The United States Deep Brain Stimulation in Parkinson’s Disease Market share is classified into product and end-use.

• The dual-channel deep brain stimulator segment dominated the market with the largest market share in 2023.

The United States deep brain stimulation in Parkinson’s disease market is segmented by product into single channel deep brain stimulator and dual-channel deep brain stimulator. Among these, the dual-channel deep brain stimulator segment dominated the market with the largest market share in 2023. Multiple brain regions can be targeted simultaneously using dual-channel systems. Thus, dual-channel brain stimulation is beneficial for patients with complicated movement problems. The increasing use of double-channel DBS with customized therapeutic strategies is driving the market in the dual-channel deep brain stimulator segment. 

• The hospitals segment dominated the US deep brain stimulation in Parkinson’s disease market with the largest market share in 2023.        

Based on the end-use, the U.S. deep brain stimulation in Parkinson’s disease market is divided into hospitals, neurology clinics, ambulatory surgical centers, and research centers. Among these, the hospitals segment dominated the US deep brain stimulation in Parkinson’s disease market with the largest market share in 2023. There is a rise in the number of DBS procedures due to the increase in the frequency of Parkinson’s disease. The utilization of cutting-edge technology in intensive care units (ICUs) and operating rooms as well as government support are contributing to propelling the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.S. deep brain stimulation in Parkinson’s disease market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Medtronic
• Abbott
• Boston Scientific Corporation
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In April 2022, the US Food and Drug Administration (FDA) approved Boston Scientific’s Vercise Neural Navigator with STIMVIEW XT, the next-generation image-guided programming software for deep brain stimulation (DBS) therapy.

• In January 2021, Medtronic plc, announced the first enrollment in ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson's Disease (PD).

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States Deep Brain Stimulation in Parkinson’s Disease Market based on the below-mentioned segments:

US Deep Brain Stimulation in Parkinson’s Disease Market, By Product

• Single Channel Deep Brain Stimulator
• Dual-Channel Deep Brain Stimulator

US Deep Brain Stimulation in Parkinson’s Disease Market, By End-use

• Hospitals
• Neurology Clinics
• Ambulatory Surgical Centers
• Research Centers